GAMBACORTI PASSERINI CARLO

Civettini, I., Zappaterra, A., Corti, P., Messina, A., Aroldi, A., Biondi, A., et al. (2025). Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype. MED, 6(4) [10.1016/j.medj.2024.11.007]. Dettaglio

Kogan, M., Alviano, A., Catalano, M., Casiraghi, A., Ghilardi, G., Rindone, G., et al. (2025). Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient. AIDS RESEARCH AND THERAPY, 22(1) [10.1186/s12981-025-00717-9]. Dettaglio

Manghisi, B., Cotilli, G., Fedele, M., Perfetti, P., Terruzzi, E., Verga, L., et al. (2025). Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy. FRONTIERS IN IMMUNOLOGY, 16 [10.3389/fimmu.2025.1563736]. Dettaglio

Fontana, D., Malighetti, F., Villa, M., Zambon, A., Gambacorti-Passerini, C., Mologni, L. (2024). Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1. LEUKEMIA, 38(8), 1843-1847 [10.1038/S41375-024-02282-Y]. Dettaglio

Smith, B., Brümmendorf, T., Roboz, G., Gambacorti-Passerini, C., Charbonnier, A., Viqueira, A., et al. (2024). Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study. LEUKEMIA RESEARCH, 139(April 2024) [10.1016/j.leukres.2024.107481]. Dettaglio